The data were compared with the 2018 ACG and 2020 AGA guidelines for UC and the 2019 ACG and 2021 AGA guidelines for CD.
Your search for tofacitinib returned 40 results
No reduction in ADRD risk seen for treatment with tofacitinib, tocilizumab, TNF inhibitors versus abatacept
JAK inhibitor baricitinib strongly recommended for the treatment of severe or critical COVID-19
The approval was based on data from a phase 3 study which evaluated tofacitinib in adults with active AS who had an inadequate response to at least 2 NSAIDs.
The update follows the FDA’s Drug Safety Communication, which was based on a completed review of a large randomized safety clinical trial evaluating tofacitinib in patients with rheumatoid arthritis.
The applications are supported by data from two 2two phase 3 induction studies and one 1 maintenance study.
The revisions are based on a completed review of a large randomized safety clinical trial, which included 4362 patients with rheumatoid arthritis.
Infliximab, adalimumab, golimumab, vedolizumab, tofacitinib, ustekinumab recommended over no tx
TNFi recommended over secukinumab, ixekizumab for AS and nonradiographic axial SpA as first biologic
Investigators assessed the risk for herpes zoster and provided recommendations regarding treatment in patients with psoriasis.